90 day analysis shows Moderna Omicron BA.1 targeting bivalent vaccine,MRNA -1273-214, demonstrates superior antibody respose as booster compared to Spikevax prototype.
Moderna, Inc. announced new clinical data on its bivalent Omicron-containing booster, mRNA-1273.214
Ninety days after administration as a fourth booster dose in previously vaccinated and boosted participants, a 50 µg booster dose of mRNA-1273.214 elicited a superior neutralizing antibody response against Omicron BA.1 when compared to a 50 µg booster dose of mRNA-1273 in all participants regardless of prior infection. Superior performance against Omicron BA.1 was also durable, with higher antibody titers sustained through three months.
In addition, mRNA-1273.214 demonstrated significantly higher neutralizing antibody responses against Omicron BA.4/BA.5 compared to mRNA-1273 28 days after administration, as previously reported. Potent responses were also seen against Omicron BA.2.75 28 days after administration, suggesting that the bivalent booster elicits broad cross-neutralization against Omicron variants. Observed side effects of mRNA-1273.214 were similar or less severe than those of either a second or third dose of the original vaccine. Additionally, no new safety concerns were identified in the three-month follow-up.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.